All In Biotech

Drug Trial Radar · NCT00504933

Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis

Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Cetirizine 10 mg for the Treatment of Seasonal Allergic Rhinitis.

Last checked: Nov 20, 2026Latest source record: Apr 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 683 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

683

Actual

Start

May 2005

Primary completion

Nov 2005

Study completion Nov 2005

Sponsor

Lead sponsor
Faes Farma, S.A.Industry
Sponsor type
Industry
First posted
Jul 20, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of seasonal allergic rhinitis.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • bilastineDrug

    20 mg (encapsulated) tablets QD/14days

  • CetirizineDrug

    10 mg (encapsulated) tablets. QD/14 days

  • PlaceboDrug

    (encapsulated) Tablets QD/14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under curve of total symptoms score (TSS) from basal visit to D14 visit, according to the patient's assessment on reflective symptoms.Time frame: 14 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.